



SANJIVANI PARANTERAL LIMITED

205, P. N. Kothari Industrial Estate, L.B.S. Marg, Bhandup (W), Mumbai - 400 078, Maharashtra

12th February 2024

To,
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

Scrip Code: 531569

ISIN: INE860D01013

Subject: Press Release

We enclose herewith a Press Release issued by the Company on Un-Audited Financial Results for the quarter ended December 31, 2023.

Please take same on your record.

Thanking You,

Yours faithfully,
For Sanjivani Paranteral Ltd.

Compliance Officer

Encl: As Above



Press Release

Sanjivani Paranteral Limited reported a strong performance for the quarter ended 31st December 2023

Mumbai, 12th February 2023: Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and two manufacturing plants at Navi Mumbai and Dehradun, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

Commenting on the results, Mr. Ashwani Khemka Chairman & Managing Director, Sanjivani Paranteral Ltd. said, “We are committed to setting new standards of excellence in patient care through our products and services. Our mission is to improve outcomes and enhance quality of life for individuals who rely on parenteral nutrition for their nutritional needs. The new geographies have performed quite well & we have a lot scope in these geographies. The fund raising has been completed.”

Financial Summary:

Q3 FY24:

- Revenue from operation grew 64% YoY to Rs. 149.6 mn.
- EBITDA margin stood at 13.1% (up 298bps YoY) led by better price realization and favorable product mix.
- Profit After Tax (PAT) grew 73% YoY to Rs. 16.5 mn. PAT margin stood at 11.0% (up 59bps YoY).

Segment-wise Performance:

- **Injectables:** Revenue grew 148% YoY to Rs. 95.8mn.
- **Oral:** Revenue de-grew 34% YoY to Rs. 33.6mn.
- **Nutraceuticals:** Revenue grew significantly YoY to Rs. 19.4mn in Q3FY24 vs Rs. 1.5mn in Q3FY23.

Market-Wise Performance:

- Exports (incl. Exports incentives) constitutes 64.8% of total revenue while domestic constitutes the rest.
- Core markets of CIS (incl Russia), Middle east & Africa and Latin America, accounted for 60.5% to Rs. 90.2mn.

9M FY24:

- Revenue from operation grew 52% YoY to Rs. 415.5mn.
- EBITDA margin stood at 14.6% (down 75bps YoY) led by lower price realization in some products.

- Profit After Tax (PAT) grew 40% YoY to Rs. 49.1mn. PAT margin stood at 11.8% (down 103bps YoY).

Hitesh Khona

Sanjivani Paranteral
Chief Financial Officer
hiteshkhona@sanjivani.co.in

Vijay Gyanchandani / Jill Chandrani

S-ancial Technologies
vijay@s-ancial.com / jill@s-ancial.com

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Sanjivani Paranteral Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.